AF
CRVS icon

Allworth Financial’s Corvus Pharmaceuticals CRVS Stock Holding History

Allworth Financial’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$908 Buy
62
+45
+265% +$718 ﹤0.01% 4596
2025
Q4 		$131 Buy
+17
New +$134 ﹤0.01% 4750

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Allworth Financial's CRVS Position: Q1 2026 in Review

Allworth Financial increased its Corvus Pharmaceuticals (CRVS) stake by 265% in Q1 2026, buying an estimated $718 and bringing the position to 62 shares worth $908. The position accounts for ﹤0.01% of the portfolio, ranked #4596.

Allworth Financial first reported a position in CRVS in Q4 2025 and has held it in 2 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Allworth Financial held 62 shares of Corvus Pharmaceuticals worth $908 as of Q1 2026.
  • Allworth Financial bought 45 Corvus Pharmaceuticals shares in Q1 2026, an estimated $718.
  • Corvus Pharmaceuticals made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #4596 holding.
  • Allworth Financial first reported a position in Corvus Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.